Keyphrases
Castration-resistant Prostate Cancer
100%
Enzalutamide
100%
Nave
100%
Androgen Receptor
33%
Targeted Therapy
33%
Post-chemotherapy
33%
Chemotherapy
33%
Acquired Resistance
33%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
33%
Receptor Targets
33%
Androgen Receptor Antagonist
33%
Disease Entity
33%
Further Treatment
33%
Treatment Advances
33%
New England Journal of Medicine
33%
Inherent Resistance
33%
Pharmacology, Toxicology and Pharmaceutical Science
Enzalutamide
100%
Castration Resistant Prostate Cancer
100%
Androgen Receptor
66%
Disease
66%
Chemotherapy
33%
Neuroscience
Prostate
100%
Enzalutamide
100%
Androgen Receptor
66%
Agricultural and Biological Sciences
Enzalutamide
100%
Androgen Receptor
66%